Video

The recognition that LT4 monotherapy is inadequate for producing symptomatic improvement in many patients has led to the formation of an international working group focused on identifying such patients. Can you share your experience with this group?

The recognition that LT4 monotherapy is inadequate for producing symptomatic improvement in many patients has led to the formation of an international working group focused on identifying such patients. Can you share your experience with this group?

Video

Can you summarize the current treatment challenges for hypothyroidism as encountered by a broad spectrum of clinicians, including primary care, internal medicine, endocrine, women’s health, and geriatric specialists?

Can you summarize the current treatment challenges for hypothyroidism as encountered by a broad spectrum of clinicians, including primary care, internal medicine, endocrine, women’s health, and geriatric specialists?

Video

What practical advice would you give to physicians who are not familiar with the specifics of how to initiate and/or monitor therapy with DTE? Are conversion tables available? Is there data to suggest which approach is better—DTE or T4/T3 (Cytomel)?

What practical advice would you give to physicians who are not familiar with the specifics of how to initiate and/or monitor therapy with DTE? Are conversion tables available? Is there data to suggest which approach is better—DTE or T4/T3 (Cytomel)?

Video

What laboratory and/or clinical features, especially persistent symptoms, suggest the need for combination therapy—including with a DTE—to optimize management? What have trials evaluating patient preferences suggested about combination therapy?

What laboratory and/or clinical features, especially persistent symptoms, suggest the need for combination therapy—including with a DTE—to optimize management? What have trials evaluating patient preferences suggested about combination therapy?

Video

Can you walk us through the typical presentation of a patient with hypothyroidism and what the guideline-adherent approach is to laboratory evaluation, clinical decision tree and initiation of therapy?

Can you walk us through the typical presentation of a patient with hypothyroidism and what the guideline-adherent approach is to laboratory evaluation, clinical decision tree and initiation of therapy?

Video

Do you recommend measuring T3 levels in patients who are not satisfied with or symptomatically burdened after being launched on T4? What factors support a decision to embark on combination T4/T3 therapy, either by adding T3 or treating with DTE?

Do you recommend measuring T3 levels in patients who are not satisfied with or symptomatically burdened after being launched on T4? What factors support a decision to embark on combination T4/T3 therapy, either by adding T3 or treating with DTE?

Video

From a front lines clinical perspective, what does the treatment roadmap for combination T3/T4 therapy look like? What approach to combination therapy do you recommend for the primary care, internal medicine, and/or women’s health specialist?

From a front lines clinical perspective, what does the treatment roadmap for combination T3/T4 therapy look like? What approach to combination therapy do you recommend for the primary care, internal medicine, and/or women’s health specialist?

Video

How do you measure clinical success in persons started on thyroid replacement therapy? What balance are you looking to strike in a treatment outcome as it relates to improved laboratory findings and improved patient well-being and quality-of-life?

How do you measure clinical success in persons started on thyroid replacement therapy? What balance are you looking to strike in a treatment outcome as it relates to improved laboratory findings and improved patient well-being and quality-of-life?

Video

Among patients who are started on combination therapy with DTE or add-on T3, what do your patients report? What is the trial-based evidence that supports use of DTE in a selected group of patients failing to respond optimally to T4?

Among patients who are started on combination therapy with DTE or add-on T3, what do your patients report? What is the trial-based evidence that supports use of DTE in a selected group of patients failing to respond optimally to T4?